Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Papulex is a dermocosmetic skincare product line specifically formulated for the management of acne-prone skin. It is a topical cosmetic range rather than a prescription pharmaceutical. The formulation typically utilizes a triple-action approach with three key active ingredients: nicotinamide (niacinamide), which provides anti-inflammatory properties; zinc PCA (Zincidone), which helps regulate sebum production; and an Anti-Bacterial Adhesive (ABA) technology (Defenskin) that prevents *Cutibacterium acnes* from adhering to skin cells. The product line includes various formats such as oil-free creams, cleansing gels, and lotions, aimed at reducing blemishes and controlling oiliness in mild to moderate acne. The brand was originally part of Sinclair IS Pharma's portfolio before being acquired by Alliance Pharma in 2015.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Papulex.